| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-01 21:30:23 UTC |
|---|
| Updated at | 2022-09-01 21:30:23 UTC |
|---|
| NP-MRD ID | NP0142863 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | (2s)-2-[(4s)-4-[(1-hydroxyethylidene)amino]-3-oxo-1,2-oxazolidin-2-yl]-5-oxooxolane-2-carboxylic acid |
|---|
| Description | Lactivicin belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. N-acyl-alpha amino acids and derivatives are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom. (2s)-2-[(4s)-4-[(1-hydroxyethylidene)amino]-3-oxo-1,2-oxazolidin-2-yl]-5-oxooxolane-2-carboxylic acid was first documented in 2007 (PMID: 17957683). Based on a literature review a significant number of articles have been published on Lactivicin (PMID: 34450571) (PMID: 31773806) (PMID: 27139464) (PMID: 24694215) (PMID: 28324428) (PMID: 23095893). |
|---|
| Structure | CC(O)=N[C@H]1CON(C1=O)[C@]1(CCC(=O)O1)C(O)=O InChI=1S/C10H12N2O7/c1-5(13)11-6-4-18-12(8(6)15)10(9(16)17)3-2-7(14)19-10/h6H,2-4H2,1H3,(H,11,13)(H,16,17)/t6-,10-/m0/s1 |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C10H12N2O7 |
|---|
| Average Mass | 272.2130 Da |
|---|
| Monoisotopic Mass | 272.06445 Da |
|---|
| IUPAC Name | (2S)-2-[(4S)-4-[(1-hydroxyethylidene)amino]-3-oxo-1,2-oxazolidin-2-yl]-5-oxooxolane-2-carboxylic acid |
|---|
| Traditional Name | (2S)-2-[(4S)-4-[(1-hydroxyethylidene)amino]-3-oxo-1,2-oxazolidin-2-yl]-5-oxooxolane-2-carboxylic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC(O)=N[C@H]1CON(C1=O)[C@]1(CCC(=O)O1)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C10H12N2O7/c1-5(13)11-6-4-18-12(8(6)15)10(9(16)17)3-2-7(14)19-10/h6H,2-4H2,1H3,(H,11,13)(H,16,17)/t6-,10-/m0/s1 |
|---|
| InChI Key | ZUEKKUYIXILDAF-WKEGUHRASA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | Not Available |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. N-acyl-alpha amino acids and derivatives are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | N-acyl-alpha amino acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-acyl-alpha amino acid or derivatives
- Dicarboxylic acid or derivatives
- Gamma butyrolactone
- Oxazolidinone
- Isoxazolidine
- Oxolane
- Acetamide
- Secondary carboxylic acid amide
- Lactone
- Carboxylic acid ester
- Carboxamide group
- Organoheterocyclic compound
- Carboxylic acid
- Azacycle
- Oxacycle
- Carbonyl group
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organic oxygen compound
- Organic nitrogen compound
- Aliphatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Sato J, Kusano H, Aoki T, Shibuya S, Yokoo K, Komano K, Oguma T, Matsumoto S, Sato T, Yasuo K, Yamawaki K: A novel tricyclic beta-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. Bioorg Med Chem. 2021 Sep 15;46:116343. doi: 10.1016/j.bmc.2021.116343. Epub 2021 Aug 11. [PubMed:34450571 ]
- Calvopina K, Dulyayangkul P, Heesom KJ, Avison MB: TonB-dependent uptake of beta-lactam antibiotics in the opportunistic human pathogen Stenotrophomonas maltophilia. Mol Microbiol. 2020 Feb;113(2):492-503. doi: 10.1111/mmi.14434. Epub 2019 Dec 11. [PubMed:31773806 ]
- Calvopina K, Umland KD, Rydzik AM, Hinchliffe P, Brem J, Spencer J, Schofield CJ, Avison MB: Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4170-5. doi: 10.1128/AAC.00371-16. Print 2016 Jul. [PubMed:27139464 ]
- Starr J, Brown MF, Aschenbrenner L, Caspers N, Che Y, Gerstenberger BS, Huband M, Knafels JD, Lemmon MM, Li C, McCurdy SP, McElroy E, Rauckhorst MR, Tomaras AP, Young JA, Zaniewski RP, Shanmugasundaram V, Han S: Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. J Med Chem. 2014 May 8;57(9):3845-55. doi: 10.1021/jm500219c. Epub 2014 Apr 21. [PubMed:24694215 ]
- Kumar KM, Anitha P, Sivasakthi V, Bag S, Lavanya P, Anbarasu A, Ramaiah S: In silico study on Penicillin derivatives and Cephalosporins for upper respiratory tract bacterial pathogens. 3 Biotech. 2014 Jun;4(3):241-251. doi: 10.1007/s13205-013-0147-z. Epub 2013 Jun 11. [PubMed:28324428 ]
- Zervosen A, Sauvage E, Frere JM, Charlier P, Luxen A: Development of new drugs for an old target: the penicillin binding proteins. Molecules. 2012 Oct 24;17(11):12478-505. doi: 10.3390/molecules171112478. [PubMed:23095893 ]
- Brown T Jr, Charlier P, Herman R, Schofield CJ, Sauvage E: Structural basis for the interaction of lactivicins with serine beta-lactamases. J Med Chem. 2010 Aug 12;53(15):5890-4. doi: 10.1021/jm100437u. [PubMed:20593835 ]
- Holzgrabe U: [Lactivicin--an antibiotic against penicillin-resistant pneumococci]. Pharm Unserer Zeit. 2007;36(6):421-2. doi: 10.1002/pauz.200790103. [PubMed:17957683 ]
- Macheboeuf P, Fischer DS, Brown T Jr, Zervosen A, Luxen A, Joris B, Dessen A, Schofield CJ: Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol. 2007 Sep;3(9):565-9. doi: 10.1038/nchembio.2007.21. Epub 2007 Aug 5. [PubMed:17676039 ]
- LOTUS database [Link]
|
|---|